Collegium Pharmaceutical (COLL) – Analysts’ Weekly Ratings Updates

by · The Cerbat Gem

Collegium Pharmaceutical (NASDAQ: COLL) has recently received a number of price target changes and ratings updates:

  • 12/8/2025 – Collegium Pharmaceutical is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $58.00 price target on the stock.
  • 12/8/2025 – Collegium Pharmaceutical was upgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b-)” rating.
  • 12/8/2025 – Collegium Pharmaceutical is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $58.00 price target on the stock.
  • 12/1/2025 – Collegium Pharmaceutical had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/24/2025 – Collegium Pharmaceutical had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/21/2025 – Collegium Pharmaceutical was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
  • 11/18/2025 – Collegium Pharmaceutical had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/8/2025 – Collegium Pharmaceutical was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
  • 11/7/2025 – Collegium Pharmaceutical had its price target raised by analysts at Truist Financial Corporation from $45.00 to $48.00. They now have a “buy” rating on the stock.
  • 11/7/2025 – Collegium Pharmaceutical had its price target raised by analysts at HC Wainwright from $44.00 to $46.00. They now have a “buy” rating on the stock.
  • 10/28/2025 – Collegium Pharmaceutical had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $46.00 price target on the stock.
  • 10/23/2025 – Collegium Pharmaceutical was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
  • 10/18/2025 – Collegium Pharmaceutical was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 30,000 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the transaction, the chief financial officer directly owned 126,667 shares of the company’s stock, valued at $5,133,813.51. This represents a 19.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the sale, the director directly owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. This represents a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.51% of the stock is owned by insiders.

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Featured Stories